TAK, US8740602052

TAK stock costs EUR 16.80 with a P/ E ratio of 52.1

Published on 10/12/2026 at 13:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Takeda Pharmaceutical stock costs EUR 16.80 on October 12, 2026. Its P/E ratio is 52.1 and market capitalization is USD 59.6 billion.

Key points in brief

TAK stock was quoted at EUR 16.80 in Stuttgart at 7:53 a.m. CEST on October 12, 2026.
Takeda's market capitalization was USD 59.6 billion and its P/E ratio was 52.1 as of October 9, 2026.
Second-quarter fiscal 2026 results are scheduled for October 29, 2026.
Bristol-Myers Squibb and GSK provide contrasting valuation and market-capitalization benchmarks.

TAK, US8740602052, Illustration mit AI erstellt.

Takeda Pharmaceutical (ISIN US8740602052) was quoted at EUR 16.80 on Stuttgart at 7:53 a.m. CEST on October 12, 2026. The market snapshot puts the company at a USD 59.6 billion capitalization and a P/E ratio of 52.1 based on October 9, 2026 figures.

Bid and ask set the opening frame

The Stuttgart quote showed EUR 16.80 on both the bid and ask at 7:53 a.m. CEST on October 12, 2026. That EUR 16.80 price is the central German-market reference for this report, while the US listing last stood at USD 18.73 at 8:00 p.m. UTC on October 9, 2026.

Trading volume for the US listing was 2,043,124 shares on October 9, 2026, against an average volume of 3,045,504 shares. The latest quote therefore came with turnover below that average, a concrete liquidity marker for investors comparing the US and German trading lines.

Valuation remains the key market metric

Takeda's P/E ratio was 52.1 and its dividend yield was 3.0 percent as of October 9, 2026. The US-listed shares stood within a 52-week range of USD 12.99 to USD 19.10, placing the USD 18.73 last price USD 0.37 below the high.

That range gives the stock a clear valuation frame, but the currencies remain separate: the German quote is EUR 16.80, while the market capitalization, P/E ratio and US range are reported in the US listing's currency. The USD 59.6 billion capitalization also makes Takeda the largest company in this comparison block.

Comparison with peers

TAK: P/E 52.1, dividend yield 3.0 percent, market capitalization USD 59.6 billion

Bristol-Myers Squibb (NYSE, USD): minus 0.8 percent, P/E 13.0, market capitalization USD 120.8 billion

GSK (NYSE, USD): minus 0.1 percent, P/E 14.8, market capitalization USD 93.2 billion

October 29 results are the next date

Takeda's investor-relations page schedules the earnings announcement for fiscal 2026 second-quarter results on October 29, 2026, with a webcast from 7:00 p.m. to 8:15 p.m. JST. The date gives the market a defined calendar point for judging revenue, earnings and management's outlook when the figures are released.

Price stays the immediate anchor

For the German market, the Stuttgart quote of EUR 16.80 at 7:53 a.m. CEST on October 12, 2026 is the immediate price anchor. The surrounding figures show a company with USD 59.6 billion in market value, a 52.1 P/E ratio and a 3.0 percent dividend yield, while the next scheduled results date is October 29, 2026.

Market context: Market report Nikkei 225.